Disruption of the thyroid-integrin signaling by use of RGD or tetrac, a specific blocker of the thyroid hormone binding site upon the integrin [16, 17], impaired the production of MMP-9 in myeloma cell lines and primary BM cells from myeloma patients. This evidence concerns the gene MMP9 and plasma cell myeloma.